In this study, the hemodynamic response and changes in oxidative metabolism during functional activation were measured using three functional magnetic resonance imaging (fMRI) techniques: the blood oxygenation level-dependent (BOLD) technique, flowsensitive alternating inversion recovery (FAIR), and bolus tracking (BT) of an MR contrast agent. With these three techniques we independently determined changes in BOLD signal, relative cerebral blood flow (rCBF), and cerebral blood volume (rCBV) associated with brain activation in eight healthy volunteers. In the motor cortex, the BOLD signal increased by 1.8 ؎ 0.5%, rCBF by 36.3 ؎ 8.2% (FAIR), and 35.1 ؎ 8.6% (BT), and rCBV by 19.4 ؎ 4.1% (BT) in response to simultaneous bilateral finger tapping. In the visual cortex, BOLD signal increased by 2.6 ؎ 0.5%, rCBF by 38.5% ؎ 7.6 (FAIR), and 36.9 ؎ 8.8% (BT), and rCBV by 18.8 ؎ 2.8% (BT) during flickering checkerboard stimulation. Comparing the experimentally measured rCBV with the calculated rCBV using Grubb's power-law relation, we conclude that the use of power-law relationship results in systematic underestimate of rCBV.
INTRODUCTION
Functional magnetic resonance imaging (fMRI) has become an increasingly important tool for the investigation of human sensory, motor, and cognitive functions. Most fMRI studies are based on T2*-weighted imaging techniques, which exploit the paramagnetic properties of endogenous deoxyhemoglobin and are sensitive to blood oxygenation level-dependent (BOLD) signal changes (Ogawa et al., 1990; Kwong et al., 1992) . The physiology underlying the BOLD effect is complex and the quantitative contribution of changes in cerebral blood flow (CBF), cerebral blood volume (CBV), and the relative metabolic rate of O 2 (rCMR O2 ) to the BOLD signal is still under investigation (Ogawa et al., 1998; Raichle, 1998) . Recently, arterial spin-labeling (ASL) techniques (Detre et al., 1992; Edelman et al., 1994; Kim, 1995) have been developed which allow the noninvasive measurement of rCBF changes during neuronal activation. Studies directly comparing ASL techniques with BOLD contrast measurements have already lead to considerable improvements in our understanding of the BOLD effect (Kim and Ugurbil, 1997; Davis et al., 1998; Li et al., 1999a; Kim et al., 1999; Hoge et al., 1999) . In addition, various theoretical models for the quantitative interpretation of BOLD signal changes have been proposed in the literature (Ogawa et al., 1993b; Buxton and Frank, 1997; Buxton et al., 1998; Davis et al., 1998; Hyder et al., 1998) . But they typically rely on assumptions made about a number of parameters, which cannot be determined directly with these noninvasive MRI techniques.
The advent of ASL techniques has also lead to attempts to estimate changes in rCMRo 2 during functional activation. Two methods have been used to estimate rCMRo 2 changes from BOLD and rCBF measurements. Based on Ogawa's (1993b) static averaging model, Kim and Ugurbil (1997) determined the average change in rCMRo 2 (5.4 Ϯ 7.3%) during visual stimulation using a flow-sensitive alternating inversion recovery (FAIR) technique in combination with BOLD measurements. Later work by Davis et al. (1998) used the effects of hypercapnia on perfusion and BOLD measurements as a calibration procedure for subsequent functional activation studies. Moderate hypercapnia was not considered to alter cortical oxygen consumption and, therefore, has been used as a reference stimulus to separate hemodynamic from oxidative metabolic contributions to the BOLD signal. Using this calibration procedure, Davis et al. reported that rCMRo 2 increased 16% with visual stimulation.
The analyses of rCMR O2 changes conducted by the above two groups are both based on a power-law relationship between CBF and CBV (CBV ϭ 0.8 CBF 0.38 ), which was established in anesthetized rhesus monkeys using an 15 O radiotracer and a single 3 ϫ 2-inch scintillation detector (Grubb et al., 1974) . However, the error introduced by using this relationship to calculate rCBV (and rCMR O2 ) changes with functional activation in humans is currently unknown. In the present study, we used sequential bolus tracking (BT) measurements of a contrast agent in addition to BOLD and FAIR measurements in order to determine rCBV changes independently.
METHODS

Materials and MRI Scanning Protocols
Eight healthy young adults (males, age 20 -36 years) participated in this study. All the measurements were performed on a GE Signa 1.5 T medical scanner (General Electric Medical Systems, Milwaukee, WI) equipped with an Echo-Speed gradient system. A custom-made elliptic birdcage coil was used with foam padding to immobilize the head. The study protocol was approved by the local Institutional Review Board. Informed written consent was obtained from all subjects before the MRI examination.
The fMRI data acquisition protocol for each subject consisted of four sessions: FAIR , BOLD, and two BT measurements. The same activation paradigm was used both for the FAIR and BT measurements. The paradigm consisted of 3 min baseline scanning, 4 min sustained activation, followed by another 2-min control period. To avoid the baseline drifts in BOLD measurements a slightly different block design was used, which consisted of six activation epochs (30 s) interleaved with six resting periods (60 s). In total, the data acquisition time for the BOLD measurements was 9 min (as for FAIR and BT experiments).
Simultaneous motor and visual stimuli were used to yield a maximum of information with only one BT experiment (ϭ2 bolus injections). The motor task was self-paced bilateral finger tapping and the visual stimulation was achieved by projecting computer-generated images into the magnetic bore. In all studies a black and white circular checkerboard with a flickering frequency of 8 Hz was used. The visual stimulus also indicated the start and end of the motor task.
The scanning procedure and acquisition parameters used for each subject were the following:
(1) Anatomical reference scanning of six transverse or oblique slices using a conventional spoiled gradient re-called echo (SPGR) pulse sequence. The scanning parameters were a matrix size of 256 ϫ 256, TE/TR ϭ 4/33 ms, flip angle ϭ 45°, and slice thickness ϭ 5 mm.
(2) Dynamic FAIR data acquisition using a singleshot multislice FAIR spiral pulse sequence with TE/TI/ TR ϭ 8/1200/3000 ms. The FAIR sequence was the same as described previously (Li et al., 1999b) . The matrix size used for this study was 64 ϫ 64 over a field view of 220 ϫ 220 mm 2 . After the inversion and tagging delay, a small bipolar gradient of 2 ms per lobe and 22 mT/m was applied simultaneously along each gradient direction followed by the readout gradient waveforms. The amplitude of the bipolar crasher was adjusted empirically to suppress the signals from the large intra-arterial spins. For each FAIR image, two inversion recovery images with and without slice-selectively gradients during the inversion pulse were acquired in an interleaved fashion.
(3) Fast T 1 mapping using the Look-Locker sequence (Look and Locker, 1970 ) with spiral readouts. After an initial inversion and short delay of 100 ms, 26 frames of images were acquired in the burst mode. A small flip angle of 20°and an interreadout delay ϭ 250 ms were used. The design of the spiral readout gradient waveforms was the same as that for the FAIR measurements.
(4) Multislice BOLD data acquisition using a singleshot spiral gradient recalled sequence (GRE) with TE/ TR ϭ 45/3000 ms and a flip angle of 90°. 180 dynamic frames were acquired for each slice. A baseline T* 2 mapping was included at the beginning of the BOLD measurement using a dual echo acquisition (Jonsson et al., 1999) . A matrix size of 128 ϫ 128 over a FOV of 220 ϫ 220 mm 2 was used for the design of the spiral readout gradient.
(5) Two successive BT data acquisitions during bolus injections using the same GRE spiral sequence as that for the BOLD measurement except for a shorter TR ϭ 1250 ms. There was a 10-min resting interval between the control BT measurement and the subsequent activation BT measurement. The two doses of paramagnetic contrast agent (gadolinium diethylenetriaminepentaacetic acid, Gd-DTPA, 0.1 mmol/kg) with and without functional activation were administered by using a MRI compatible power-injector (Medrad Inc., Pittsburgh, PA) at a rate of 5 ml/s via an antecubital vein. To ensure steady data acquisition, the second dose was always injected at 90 s after the onset of the sustained stimuli.
MR Image Data Processing and Statistics
The image reconstruction was performed off-line on a SPARC workstation (Sun Microsystems, Mountain View, CA) using a gridding algorithm outlined previously (Li et al., 1998) . The reconstruction routine also used an acquired B 0 field map to correct for linear shim terms and carrier frequency offset in each slice (Li et al., 1998) . All data sets collected in this study were screened for motion artifacts by viewing the time series in CINE mode using the software MRVISION (MRVision Co., Menlo Park, CA). The auxiliary program, imreg, included in the fMRI software AFNI (Cox, 1996) was used for image registration, which minimizes the mean squared error between the selected reference image and the images to be registered. Bicubic interpolation was used to resample the images.
T 1 maps were evaluated using the previously established procedure (Kay and Henkelman, 1991) for LookLocker data set. The FAIR images were calculated by magnitude subtraction of the nonselective inverted images from the selective inverted images (Li et al., 1999a, b) . CBF quantification from FAIR measurement was based on the perfusion model of Detre et al. (1992) . The baseline data collected prior to the onset of the sustained activation was used as a reference to calculate the relative CBF changes induced by the activation. Since each FAIR image requires a pair of images with selective and nonselective inversion, the temporal resolution of the FAIR data was 6 s with a TR of 3 s.
The time series of FAIR and BOLD data were analyzed with the Student t test statistics on a pixel-bypixel basis. For each t map the statistical significance of the activation was assessed by the same t score thresholding and cluster analysis. After including a multiple comparison correction, using a threshold t score Ͼ 3.2 guaranteed that the significance P was less than 0.001. A minimum cluster size of 5 pixels was also implemented to produce the final activation maps. The activation induced BOLD and FAIR signal changes in the motor and visual cortexes were evaluated by analyzing the mean time courses of the voxels in the activated areas. Time locked averaging (Glover, 1999) was used to obtain the percent changes of BOLD and rCBF from the mean time courses. The mean time course was determined by taking the average value of the signal intensities of the voxels that were activated in both FAIR and BOLD measurements. Choosing the commonly activated regions is equivalent to a logical "and" operation on the BOLD and FAIR generated activation maps. Although the signal-to-noise ratio of the FAIR data is lower than the BOLD data, the functional contrast for FAIR measurements is much higher (35-38% versus 1.8 -2.6%). The contrast-to-noise ratios that determine the sensitivity for activation detection are quite comparable between FAIR and BOLD measurements at 1.5 T. The activation volumes detected by BOLD and FAIR are comparable; however, it has been consistently observed by many investigators that activation detected by FAIR and BOLD measurements only partially overlap (Luh et al., 2000) . The BOLD signal contains a larger contribution from CSF, since the draining veins are usually surrounded by CSF. Taking the overlap portions of the activation between FAIR and BOLD would eliminate CSF contaminations.
Bolus tracking data was analyzed as previously described by Østergaard et al. (1996a,b) . Intravascular contrast agent concentrations, C(t), were estimated assuming a linear relationship between concentration and change in transverse relaxation rate, using equation
where s(t)/s(0) is the normalized signal intensity during the bolus injection against the baseline signal intensity before bolus arrival, is the normalization factor to convert signal changes to tracer concentration. Then, the arterial input function was manually determined in each subject from pixels containing relatively large feeding vessels (typically the middle cerebral artery), showing an early and large decrease in signal intensity following the contrast injection. Finally, deconvolution was performed over the range of images where the arterial input values exceeded the noise level using the singular value decomposition algorithm to determine CBF from bolus tracking data. Once CBF was known, the CBV was derived from the bolus tracking raw data using numerical integration of the concentration time course. The mean transit time was further determined as the ratio between CBV and CBF. According to Østergaard et al. (1996a,b) , this approach can determine the flow with reasonable accuracy and the results are independent of the underlying vascular structure and volume. However, for absolute quantification of CBF and CBV, a calibration procedure is needed to determine the scaling factor, , in Eq. (1). Previous studies have successfully used coregistered PET (Østergaard et al., 1998a, b) and FAIR (Li et al., 1999c) data as a calibration reference.
In the present study, we were only interested in evaluating the relative changes of CBF and CBV induced by activation. The time interval (10 min) between two successive BT measurements was short relative to the clearance time of the contrast agent from the body (hours). The effect of residual contrast agent from the first BT measurement to the following BT measurement has to be corrected for accurate assessment of the relative changes of CBF and CBV due to functional activation. Figure 1 shows a representative set of time courses from a nonactivated region during two successive BT measurements (corresponding to resting and activation states). The residual contrast effect is evident in the time courses. Previous fMRI studies based on sequential BT measurements completely ignored the residual contrast effect (Belliveau et al., 1991; Zigun et al., 1993; Frank et al., 1994) . In the present study we have carefully implemented a correction scheme to handle this problem. The basic idea of this correction procedure is based on the fact that the measured regional CBF and CBV values in nonactivated areas should be the same during two successive measurements.
The activation maps obtained from BOLD and FAIR measurements were used as a mask to select the nonactivated regions of interest (ROIs). In each slice, 12 circular ROIs (each contained 28 pixels) were chosen in nonactivated gray and white regions using a custom made program. The anatomically matched ROI values of CBV and CBF from all slices in two successive bolus injections were analyzed using a linear regression method. The extracted linear regression parameters for each subject were used to rescale the corresponding CBV and CBF values from the second BT measurements on a pixel-by-pixel basis so that the CBV and CBF values in the nonactivated pixels matched precisely. The same scaling factors were also applied to the activated regions. The corrected CBV and CBF maps for the resting and activation states were subtracted to reveal areas involved in the functional tasks using a threshold of 2ϫ SDs above the mean of the subtracted images. The relative CBV and CBF changes associated with the functional activation were determined from the subtracted images as the mean values of the voxels that were activated in both BOLD and FAIR measurements. For further validation of the correction procedure, linear regression analysis was also conducted between CBF results from BT and FAIR measurements using the same method as outlined above. Figure 2 shows a representative set of perfusion maps obtained from a BT measurement in one of the subjects. The gray and white matter contrast is very apparent in the CBF and CBV maps, but MTT appears to be quite homogeneous in the entire brain except for regions contaminated by cerebrospinal fluid (CSF). As expected, residual contrast agent effects became apparent when analyzing the rCBF and rCBV data obtained during rest (1st injection) and activation (2nd injection). Linear regression analysis of CBF and CBV values in nonactivated ROIs, where we assumed that both parameters did not change, demonstrated a highly significant linear correlation (Table 1; Figs. 3 and 4), but the slope of the regression curves was not equal to one (average ratio: CBF2/CBF1 ϭ 1.63; CBV2/ CBV1 ϭ 0.87). We corrected the residual bolus effects by normalizing the second CBF and CBV values to the values obtained with the first bolus injection on a pixelby-pixel basis.
RESULTS
With simultaneous motor and visual stimulation, activation in the primary sensorimotor cortex (M1), supplementary motor area (SMA), and primary visual cortex (V1) were observed in all subjects (Fig. 5) . There was generally good agreement in activation responses between BOLD, FAIR, and BT measurements; however, there are observable differences in terms of the spatial extent of activation. The activation volumes detected by BOLD and FAIR are quite comparable, but BOLD and FAIR measurements only partially overlap.
Percentage changes of BOLD, FAIR, rCBF, and rCBV induced by the stimuli are summarized in Tables  2 and 3 for each subject. The data were calculated for pixels activated in both BOLD and FAIR measurements and should be relatively free from large vessel contribution because of the macrovascular suppression of the FAIR measurements. The average rCBV and rCBF values in the motor cortex increased by 19.4 Ϯ 2.7 (range 15.7-25.4) and 35.1 Ϯ 8.6% (range 21.4 -45.7), respectively. The corresponding rCBV and rCBF changes in the visual cortex were 18.2 Ϯ 2.8 (range 14.0 -21.7) and 36.9 Ϯ 8.8% (range 22.6 -48.8), respectively. The percentage BOLD signal changes in motor and visual cortexes were 1.8 Ϯ 0.5% (range 1.4 -2.6) and 2.6 Ϯ 0.5% (range 2.1-3.1), respectively. The BOLD and FAIR results are consistent with the data from previous studies using similar experimental conditions (Kwong et al., 1992; Kim and Ugurbil, 1997; Kastrup et al., 1999; Davis et al., 1998) .
FIG. 1.
A typical set of time course of the MRI signal intensities in a nonactivated region during two successive bolus injections of Gd-DTPA contrast agent. The data were extracted from the same ROIs containing only pixels over major vessels. The corresponding concentration time courses are also depicted, which were used as arterial input functions for the deconvolution computations.
DISCUSSION rCBV Quantification
Only a few human fMRI studies have investigated changes in rCBV during functional activation (Belliveau et al., 1991; Zigun et al., 1993; Frank et al., 1994) . For the quantification of rCBV, current MRI methods require the administration of contrast agent, which has limited number of repeatable measurements and temporal resolution. In the first fMRI study reporting changes related to brain activity in human activation (Belliveau et al., 1991) , sequential bolus injections of paramagnetic contrast agent were used to assess rCBV. The reported rCBV change in response to visual stimulation over seven subjects was 32% (Belliveau et al., 1991) . In this early study (Belliveau et al., 1991) and all subsequent studies (Zigun et al., 1993; Frank et al., 1994) it has assumed that the signal intensity-time profile of the second bolus injection was not influenced by the first bolus injection. Recently, however, it has been shown that residual contrast from the first injection can give rise to systematic errors in subsequent BT measurements (Levin et al., 1995) , indicating that it is essential to correct for the residual contrast effect when determining rCBV changes with BT.
In this study, the residual contrast effect on the second BT measurement was corrected assuming that CBV (and CBF) do not change in non-activated brain areas between the two bolus injections. The correction involved two steps: First, we established that there is a good linear correlation between the data sets from the two successive BT measurements in nonactivated regions. Using the value obtained for the slope of the regression curve, we then corrected the CBF and CBV data from the second BT measurement to match the values obtained with the first BT measurement. The   FIG. 2 . A representative set of rCBF, rCBV, and rMTT maps measured with BT. Grey/white matter differences are evident in the rCBF and rCBV images, whereas rMTT maps are quite homogeneous in the entire brain except for regions contaminated by CSF.
validity of this correction procedure is indirectly supported by our finding that there is a significant correlation (r ϭ 0.87 and P Ͻ 0.01) between the CBF data measured with BT and FAIR techniques.
After correcting for residual contrast effects, the average change of rCBV during visual stimulation was found to be lower than reported in the initial fMRI study activation (Belliveau et al., 1991) using double Note. CBF and CBV measured in two successive BT experiments are linearly correlated. CBF measured by BT and FAIR methods are also linearly correlated. The ratio (a), intercept (b), and Pearson product-moment coefficient (r) between the first (CBF1 and CBV1 at resting state) and second (CBF2 and CBV2 at activation state) measurements are listed.
FIG. 3. Correlation between rCBV values from nonactivated
ROIs obtained in two successive BT measurements (resting versus activation).
FIG. 4. Correlation between rCBF values from nonactivated
BT measurements (18.2 vs 32.2%). In the PET literature, on the other hand, rCBV increases between 2 and 20% have been reported with different functional activation paradigms (Fox and Raichle, 1986; Roland et al., 1987; Fox et al., 1988) . More recent fMRI studies in rats (Mandeville et al., 1998 ) used intravascular contrast agents with a very long blood half-life (iron oxide particles) to investigate rCBV changes associated with hypercapnia and focal neuronal activation. Using this technique, Mandeville et al. (1998) reported a rCBV increase of 24% in response to electrical stimulation of rat forepaw, which is comparable to our findings in human motor cortex (19.4%) and visual cortex (18.2%). 
CBV and CBF Relationship
As outlined above, rCBV is frequently estimated from measured rCBF values using the equation CBV ϭ 0.8 CBF 0.38 . This power-law relationship was established by Grubb et al. (1974) in anesthetized rhesus monkeys for different degrees of hypercapnia using an 15 O radiotracer and a single 3 ϫ 2-inch scintillation detector. As shown in our study, the application of this CBF/CBV relationship to different individual human subjects may lead to errors when estimating rCBV and rCMO2 changes with functional activation. The estimated rCBV values using Grubb's equation CBV ϭ 0.8 CBF 0.38 were consistently lower than the measured rCBV values (Tables 2 and 3 ). These results indicate that caution must be applied when using the above stated power-law relationship to estimate rCBV (and rCMR O2 ) changes during functional activation in humans.
It is also questionable if the CBF-CBV relationship established by Grubb et al. for hypercapnic stimuli can be applied to neuronal activation. First of all, the CBF regulatory mechanisms for hypercapnia and neural activation are likely to be different. Second, the relationship between rCBV and rCBF may deviate from Grubb's relationship with changes in cerebral metabolism, which occur with functional activation, but not with hypercapnia. In addition, as recently shown by Mandeville et al. (1999) in animal studies, the CBF-CBV ratio changes dynamically during focal stimulation due to the comparatively slower evolution of rCBV changes (Fig. 6 ). This is in agreement with models relating the brain vasculature to changes in BOLD signal, CBF and CBV changes during functional actiavation. CBF and BOLD responses are probably largely determined by arteriolar vasocontrol where 70% of cerebral vascular resistance occurs and the response is relatively fast, whereas the CBV response is predominantly due to volume changes in the (capillaries) and veins and the dilation is slow and passive.
CONCLUSIONS
We have demonstrated that BOLD fMRI signal changes can be expressed as a function of T2*, rCBF, and rCBV using Fick's law for oxygen delivery in the brain. With multimodality fMRI measurements including BOLD, FAIR, and bolus tracking of contrast agent, all of these parameters can be determined and the contribution of hemodynamic and oxidative metabolic parameters to BOLD signal changes can be assessed quantitatively. Comparing the measured rCBV with the calculated rCBV using Grubb's power-law relation, we conclude that the use of power-law relationship to estimate rCBV from rCBF may give rise to systematic errors in the estimated rCMR O2 . (Grubb et al., 1974) . Literature results from PET study in human (Fox and Raichle, 1986) and fMRI study in rat using longlived intravascular contrast agent (Mandeville et al., 1999) are also depicted.
